Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 0.68 |
| ▸ | GPR183 | P32249 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14386912 | 1.00 | CCR2 (0.68) | CCR2GPR183NPC1RAB9ATDP1 | |
| SCHEMBL5328945 | 0.83 | CCR2 (0.72) | CCR2GPR183NPC1RAB9ATDP1 | |
| SCHEMBL5464273 | 0.83 | CCR2 (0.72) | CCR2GPR183NPC1RAB9ATDP1 | |
| SCHEMBL18840986 | 0.81 | CCR2 (1.00) | CCR2GPR183NPC1RAB9ATDP1 | |
| SCHEMBL5325878 | 0.79 | CCR1 (0.44) | CCR2 | |
| SCHEMBL5326232 | 0.79 | NPC1 (0.59) | CCR2GPR183NPC1RAB9ATDP1 | |
| SCHEMBL5326228 | 0.79 | NPC1 (0.59) | CCR2GPR183NPC1RAB9ATDP1 | |
| SCHEMBL14387101 | 0.77 | CCR2 (0.77) | CCR2NPC1RAB9A | |
| SCHEMBL5330013 | 0.77 | CCR2 (0.77) | CCR2NPC1RAB9A | |
| SCHEMBL4505167 | 0.75 | NPC1 (0.69) | CCR2GPR183NPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | claimed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | claimed |
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | CCR2 1/4885GPR183 120/4885NPC1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.